| Similar Articles |
|---|
 |
Managed Care
December 2003
David M. Pariser |
Treating Psoriasis Patients With Biologic Agents Improved outcomes with new biologic agents are prompting physicians to integrate them into therapy for psoriasis patients.   |
American Family Physician
February 15, 2006
Luba & Stulberg |
Chronic Plaque Psoriasis Patients and physicians should understand that psoriasis is a chronic disease without a cure, and that it is important to have realistic expectations of treatment. Treatment should focus on improvement, not disappearance, of lesions. |
Managed Care
June 2003
Thomas Morrow |
The 'Heartbreak of Psoriasis' Has Met Its Match! New therapies that manipulate the immune system offer hope to patients and pose challenges to managed care. |
American Family Physician
February 15, 2006 |
Psoriasis: What You Should Know A patient information guide: What is psoriasis... Who gets it and why?... How do I know if I have psoriasis?... How is psoriasis treated?... What can I expect?... |
American Family Physician
October 15, 2003 |
Psoriasis What is psoriasis?... Is psoriasis contagious?... How is psoriasis treated?... Will psoriasis go away with treatment? |
Managed Care
May 2006
Thomas Morrow |
Cost Effective Psoriasis Treatment May Demand Creative Coverage Rules While biologic agents can be costly, a new formulation of an old treatment can mean inexpensive and effective relief. |
The Motley Fool
October 8, 2010
Brian Orelli |
Pfizer's Rash (of Bad News) Is Over Data from Pfizer's phase 2 trial testing tasocitinib against psoriasis, a painful autoimmune skin disease, looks promising even given its small size. |
AskMen.com
Dustin Driver |
Common Skin Disorders The following skin afflictions are usually embarrassing and sometimes very serious. Thankfully, with a little help from your doctor, they can be treated and managed. |
Nursing
February 2009
Daniel A. Hussar |
New Drugs 09: Part 1 Learn about 10 new drugs, including nebivolol HCl, the newest beta-adrenergic blocking agent for hypertension. |
Pharmaceutical Executive
February 1, 2012
Ben Comer |
Best to Market Pharm Exec's Brand of the Year: Abbott's Humira |
Managed Care
January 2007 |
The Use of Therapeutic Interchange For Biologic Therapies The stated goal of therapeutic interchange is to achieve an improved or neutral outcome with the new agent while reducing overall treatment costs. |
Nursing
June 2010
Daniel A. Hussar |
New drugs 2010, part 2 In this article, you'll learn about 14 recently marketed new drugs. |
The Motley Fool
January 22, 2008
Brian Orelli |
The Little Anti-Inflammatory That Could Abbott Laboratories gets yet another approval for Humira, this time to treat chronic plaque psoriasis. |
American Family Physician
December 1, 2001
John Koo |
Psychodermatology: The Mind and Skin Connection Psychodermatology, or psychocutaneous medicine, focuses on the boundary between psychiatry and dermatology. Understanding the psychosocial and occupational context of skin diseases is critical to the optimal management of psychodermatologic disorders... |
The Motley Fool
June 26, 2009
Brian Orelli |
The $16 Billion Market That Could Make You Rich A large market just waiting to be taken over. |
The Motley Fool
February 10, 2004
David Nierengarten |
The Psoriasis Wars The pharma heavies are battling for the chronic skin disease's market. |
American Family Physician
October 1, 2000
Kelly W. Jones, Pharm.D. & Supen R. Patel, M.D. |
A Family Physician's Guide to Monitoring Methotrexate Although the drug is usually prescribed by a subspecialist, a family physician may assume responsibility for monitoring methotrexate therapy... |
The Motley Fool
April 8, 2005
David Nierengarten |
The Psoriasis Wars Continue Biogen-Idec hopes its new drug will conquer the lucrative psoriasis market. Investors should consider taking a second look at the company's prospects. |
Managed Care
July 2006 |
Specialty Anti-Inflammatories See Huge Increase in Utilization Americans spent 34% more for specialty anti-inflammatory agents used to treat rheumatoid arthritis in 2005 than any other specialty drug category. |
The Motley Fool
March 4, 2011
Brian Orelli |
Pfizer's Biggest Shot at Lipitor 2.0 It might need a little help from competitors. |
The Motley Fool
October 4, 2007
Brian Orelli |
Stopping the Inflammation Johnson & Johnson subsidiary Centocor announces positive phase 3 data for its psoriasis drug. Given the strong results from the trial, the company plans to file a marketing application for the drug by the end of the year. |
